الفهرس | Only 14 pages are availabe for public view |
Abstract Cytomegalovirus (CMV) infection is the single most frequent infectious complication in renal transplant recipients. CMV infections were associated with decreased patient survival, graft survival. Methods: This single-center, retrospective study includes 611 patients who received renal allotransplantation from January 2003 to December 2009 at Mansoura Urology and Nephrology Center. We detected that 62 (10%) patients were infected with CMV disease (study group), this group was compared with 62 patients were not infected with CMV disease (control group) .all the patients didn’t receive any prophylaxis for CMV.CMV PCR was used to diagnose CMV disease posttransplantation. Results: the Prevalence of CMV disease was 10% .pre-transplant CMV IgG was positive in both groups, in both donor and recipient. The mean onset for CMV disease was 71±48 days post transplantation. In our study (40.7%) of patients who received Alemtuzumab (Campath- 1H) developed CMV disease, compared to (6.9%) to those who received Basiliximab. Acute rejection through the first year post transplantation in CMV infected patients was significant (p-value 0.03). There was significant difference regarding graft survival (p-value >0.05) and patient survival (p-value >0.05) between study and control group, both patient and graft survival were significantly lower in the CMV diseased group. |